Table 3. Reported coronavirus disease 2019 vaccine adverse event grouped by gender.
Characteristic | Gender | p-value | |||
---|---|---|---|---|---|
Male | Female | Unknown | |||
Age (yr) | 0.829 | ||||
12–55 | 29 (60.4) | 97 (64.2) | 1 (100.0) | ||
>55 | 19 (39.6) | 54 (35.8) | 0 | ||
Vaccine | 0.057 | ||||
Pfizer-BioNTech | 42 (87.5) | 139 (92.1) | 1 (100.0) | ||
Moderna | 2 (4.2) | 11 (7.3) | 0 | ||
Janssen | 4 (8.3) | 1 (0.7) | 0 | ||
Local reaction | 4 (8.3) | 13 (8.6) | 0 | 0.601 | |
Erythema at the injection site | 0 | 1 (0.7) | 0 | ||
Pruritus at the injection site | 0 | 1 (0.7) | 0 | ||
Pain at the injection site | 3 (6.3) | 7 (4.6) | 0 | ||
Reaction at the injection sitea) | 1 (2.1) | 4 (2.6) | 0 | ||
Systemic reaction: top 10 systemic reaction | 0.002* | ||||
Fatigue/asthenia | 17 (35.4) | 61 (40.4) | 0 | ||
Pyrexia/increased body temperature | 16 (33.3) | 43 (28.5) | 0 | ||
Headache | 13 (27.1) | 58 (38.4) | 0 | ||
Pain (general)/pain in extremity/myalgia | 19 (39.6) | 44 (29.1) | 0 | ||
Chills | 12 (25.0) | 51 (33.8) | 0 | ||
Arthralgia/joint swelling/joint stiffness/joint range of motion decreased/musculoskeletal stiffness | 10 (20.8) | 18 (11.9) | 0 | ||
Dizziness | 4 (8.3) | 18 (11.9) | 0 | ||
Nausea | 3 (6.3) | 17 (11.3) | 0 | ||
Peripheral swelling/eye swelling/face swelling/pharyngeal swelling/oedema/lip swelling/swelling | 0 | 15 (9.9) | 0 | ||
Feeling abnormally/hot or cold | 1 (2.1) | 11 (7.3) | 0 |
Values are presented as number (%). Data extracted from the Vaccine Adverse Event Reporting System and stratified by gender [4].
*p<0.05 (statistically significant). a)Injection or vaccination site reaction included multiple parameters (i.e., pruritus, pain, swelling, redness, bruising, warmth, irritation, and/or erythema).